Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early phase II study of RBM-007 in children with achondroplasia
jRCT2031220291Phase 2Completed
- Sponsor
- Ribomic Inc.
- Start
- Apr 2023
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of umedaptanib pegol in achondroplasia (ACH) (2 arms), sponsored by Ribomic Inc. Primary endpoints: Height growth velocity comparison, Serum biomarkers and 9 more. Started Apr 2023; status: completed.
02
Drugs
umedaptanib pegol
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on jRCT2031220291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220291.